U.S. Markets closed

InVivo Therapeutics Holdings Corp. (NVIV)

NASDAQ Global Market - NASDAQ Global Market Delayed Price. Currency in USD
Add to watchlist
1.225-0.025 (-2.000%)
At close: 4:00PM EDT
People also watch
AVXLCURONCSADXSBCLI
  • f
    frank
    frank
    I find it very alarming NVIVs upper management arent gobbling up shares at these levels. If the scaffold was truly a game changer investors would be buying in droves instead crickets.
  • R
    Rich
    Rich
    Although in small amounts, the past five weeks, the AVXL CEO has been buying his company's shares. At $40K per week, for 3 years with free housing, Marko should plow some of that money into INVIVO shares showing us his commitment to shareholders
  • L
    La
    La
    What's the latest on patient #1, Jordan? I really thought he would be walking unassisted by 1 year. Its been almost 3 years now? Is that right? Does anyone know his latest condition?
  • S
    Steve
    Steve
    IBB up 5 1/2 points and this thing can't move up?
    I keep thinking the song that BB King sang
    THE THRILL IS GONE
  • S
    Steve
    Steve
    Ken with regard to AST. Last week you were very optimistic about their cohort study and today and I would believe it is you on the AST board

    Quote'

    Looking at the trials and interim results is interesting. Results to date are looking positive but far from miraculous. Regarding the actual trial design, historical data is being used as a substitute for a real time control. This is a time and money saving approach that has been used before. However, in this application. this surrogate control unfortunately lacks one experimental variable necessary for it to be acceptable. The control group needs to be administered tacrolimus in order to isolate and measure effects of the cell doses. A major design flaw such as this could invalidate the entire trial. When presented to FDA for marketing approval this could become a show stopper imo.

    Why do you flip flop on their cohort trial design? One day good the next day bad? your comment with regard to their trial "invalidate the entire trial" is somewhat disturbing
  • k
    ken
    ken
    I cannot believe this situation. Friends and family invested based on the science. The science has passed the test unless some of the reported results have been falsified. This would be criminal behavior and unbelievable. Why else would insiders not buy shares? What do they know? My potential loss as a long term investor is huge. I cannot explain the CEO lack of polish and misdirected judgment but the consequences are painful for way too many early investors. As a long ago spinal injury patient I value the science in an emotional and economic way especially with regard to newly paralyzed young people. NVIV twiddles as their window of recovery closes and shareholders struggle to understand why our company has shifted INSPIRE into neutral.
  • J
    Jnsnintrcptr
    Jnsnintrcptr
    Jesi will be jumping rope soon!
    Get this thing going!!!
    Crazy
  • M
    Materazzi
    Materazzi
    RIP Jerry! If there is a heaven and you can buy yourself in with good deeds and charity, you must be feeling pretty good about now.
  • D
    Dude
    Dude
    Portrait of a qrappy CEO
    Mark Perrin, failed CEO of Conjuchem
    Latest achievements:
    Despite clear proven advances in medical success of a phase-3 HDE study in support of FDA approval, and no safety issues, this milquetoast has presided over a 90% evaporation of market capitalization as he hasn't got one iota of a clue how to support the value of the company. To the extent that he may be allowed to do so (one needs to be a creative out of the box thinker), he has not kept up the enthusiasm in the trial sites and probably has failed in the routine review and oversight, leading to complacency of the sites and a poor capture rate, delaying the study tremendously. Thise sites who have stepped up to the plate have recruited highly risky patients to make up for the slackers in other sites who have done nothing. This has lead to unrelated deaths due to the poor condition of those patients! Moreover, this failure of a CEO has not figured out (as the eccentric Reynolds did before him) how to excite the investment community by properly SELLING the merits of the technology and future value of the company. When you're a milquetoast and a wimp, (and a prior failure) that's what happens. Furthermore, silent Mark could have at least purchased company stock with his outrageously GENEROUS disposable income, including undeserved bonus for hitting only 50% of the corporate target.

    Attention Board of Directors: Simultaneously replace this dud of a CEO with the announcement of the restart of INSPIRE (with renewed focus on a quick completion) and watch this stock soar 300% and then more after the patients roll in.
  • S
    Steve
    Steve
    Where's the new MP. Your a useless CEO
  • S
    Steve
    Steve
    Looking at all the comment's I bet investor relations is being bombarded with E-Mails. I've sent the 5 in the past 3 hours.
    Let's hope everyone has.
    I'm sure the BOD's are forwarded comments
    From what I understand these BOD's make around $65,000 a year
    Time to earn your keep
  • D
    Dude
    Dude
    Two things would boost the share price tremendously: (like over $4)

    1. Announcement of INSPIRE resuming recruitment
    2. Replacement of Mark Perrin with a more skillful CEO

    Bonus: An authoritative restatement of the already known fact that patient deaths have nothing to do with the NSS and procedure. That recruitment of patients have tended toward the more risky due to missed opportunities by study sites to recruit less risky patients.
  • D
    DorothyG
    DorothyG
    I have lost any faith in this company as a long time stock holder. I would be ashamed to be on their board. I have written the public relations office with questions and comments on many occasions with not one answer. I was partially motivated to invest in this stock because they were working to accomplish something good for humanity. It certainly has been. a total loser as an investment and it just keeps getting worse. It is so low that it isn't even worth selling except for a loss. Shame on management!!!
  • S
    Steve
    Steve
    saracen18662 with 37 people at the company working on something that is halted what do they do all day.
    T'm sure they are social media sorts and get on facebook and other social media sites reading about the ineptitude of management. The only two people that are working at this company are the receptionist (who at this point probably deserves a bigger bonus then king dackhead for having to field calls about this incmpetent bird brain). The other person that has a job to do is the bookkeeper cutting checks for the staff.
  • s
    saracen1866
    saracen1866
    I propose that while the share holders continue to get their #$%$ handed to them, management donate their unearned salaries to children's charities...this at least would make me feel better. Share the pain.
  • D
    Dude
    Dude
    The MP report, August 17, 2017.

    The CEO has failed this company and he has failed its investors both retail and institutional. How many months has he been like a deer in the headlights and has made poor decision after poor decision. He's been a horrific steward of the company funds. He has presided over 90% evaporation of the market cap, during which time the company has ironically made strides forward, albeit in low gear. This failed CEO has not had the wherewithal to convey to Wall Street the intrinsic value of the future product. Furthermore, within the strict constraints of how to deal with the PI's and their staffs at the study sites, he has failed to keep up enthusiasm. This failure has lead to excessive complacency and missed opportunities to capture a high percentage of patients into INSPIRE. So much so, that they have recruited a disporoportionate amount of patients with huge risk of death. That could have been totally avoidable had more sites stepped up to the plate and not let so many patients fall through the cracks. About all this has served to do is to put to bed the ridiculous short theory of alleged selection bias, which is the most absurd notion one can imagine. But what good is disproving a ridiculous theory when the study could have been completed and attained approval had the recruitment not missed so many qualified patients.
  • r
    rkomd
    rkomd

    If you want to know the real reason the stock is this low, check out the level of illegal naked short selling. http://nakedshortreport.com/?index=NVIV

    Naked Short Report, Nasdaq and NYSE Naked Short Positions, Short Selling Interest
    Naked Short Report - track short selling interest on NASDAQ and NYSE STOCKS, check daily short interest, naked short data and short squeeze stock perfomance
    nakedshortreport.com
  • E
    Erickarther
    Erickarther
    A product that appears to be able to pass trial and a PPS that appears to be going sub 100 pennies....I wouldn't believe it but yet we're watching it happen.
  • D
    Dude
    Dude
    Although the share price is pathetically low, and up until recently unjustifiably so, the latest "strategic" moves a/k/a fumbles by Perrin have delayed the long play, so actually it is anyones guess what happens next. The warrant conversion was a protective measure or stopgap to guard against that being a larger liability (so that is supporting the SP after its drop), but the unknown delay time is unfortunate. Only 4 more patients to enroll and go 6 months, but this holding pattern really throws it up in the air.
    A couple things to note: Although there is no evidence linking patient deaths with INSPIRE (good), we have an indeterminate delay (bad), though the fact that there have been fatalities ought to put to bed the ridiculous short speculation of "selective bias" which was always an absurd thesis, and even more repudiated by the desperateness of PI's flirting with using such fragile patients. Obviously no cherry-picking going on! They need to get INSPIRE going again as quickly as possible. I understand the sites need to sign off on any changes, but why can't the study resume at the individual pace of sites coming back online. Probably the ones who were not Hall of Shame contenders (active sites instead of on paper only) will sign off more quickly anyway, so a staggered restart should be fine. I find it hard to believe that it is all or nothing like a jury needing to be unanimous or there's a retrial. Anyway time is of the essence. Long thesis on temporary hold thanks to Perrin's mismanagement.
  • f
    frank
    frank
    I have a feeling Perrin is going to have a very hard time finding some savvy investor to take his next offering. Thats going to lead to what Perrin does best and thats BK.